Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs Novo Nordisk A/S (NVO) Price & Performance

Google IncTrade
Novo Nordisk A/STrade

Price performance (Past 24H)

Key statistics

Google Inc vs Novo Nordisk A/S — how do they compare? Google Inc trades at $342.27 (market cap $4.20T), while Novo Nordisk A/S trades at $46.22 (market cap $207.85B). The key difference: Google Inc is far larger — about 20.2× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.

GOOGNVO
Market Cap
$4.20T$207.85B
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$63.98
52-Week Low
$200.19$35.29
Enterprise Value
$4.09T$222.55B
Dividend Yield
0.26%3.81%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $340.22, down 4.39% over 24 hours, with a bearish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals, with revenue growing from $282.8B in 2022 to $402.84B in 2025 and net income margin expanding to 32.8%. Recent earnings beats and a consensus analyst price target of $431.67 suggest upside potential, though high capital expenditure plans and regulatory scrutiny pose risks.

The outlook remains positive due to robust AI adoption, with Gemini reaching 1 billion users, but investors face headwinds from elevated capex and antitrust investigations. Wall Street sentiment is overwhelmingly bullish, with 86.84% of analysts rating it a buy, highlighting growth prospects amid competitive and regulatory challenges.

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $46.28, down 3.05% today, with technical indicators showing neutral signals. The company maintains strong fundamentals with Q2 2026 EPS beating expectations at $0.96 versus $0.77 estimate, continuing a pattern of earnings outperformance. Revenue growth remains solid with 2025 revenue reaching $309.1B and net income margin of 33.14%. Analyst sentiment remains positive with 57.9% recommending Buy, though recent news highlights competitive pressures from Eli Lilly in the GLP-1 market.

NVO presents a compelling investment case with robust profitability metrics including 59.82% ROE and attractive valuation at 11.62 P/E. However, increasing competition in weight-loss drugs and pricing pressures create headwinds. The stock's current technical neutrality suggests potential consolidation near current levels, with fundamental strength supporting long-term growth prospects despite near-term competitive challenges.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO